Spero Therapeutics Inc (NASDAQ:SPRO) – Stock analysts at Oppenheimer boosted their Q1 2018 earnings per share (EPS) estimates for shares of Spero Therapeutics in a report released on Tuesday, April 3rd. Oppenheimer analyst J. Olson now expects that the company will post earnings per share of ($1.67) for the quarter, up from their prior forecast of ($2.34). Oppenheimer currently has a “Buy” rating and a $30.00 target price on the stock. Oppenheimer also issued estimates for Spero Therapeutics’ Q2 2018 earnings at ($1.31) EPS, Q3 2018 earnings at ($1.58) EPS, Q4 2018 earnings at ($1.11) EPS, FY2018 earnings at ($5.43) EPS, FY2019 earnings at ($5.83) EPS, FY2020 earnings at ($6.54) EPS and FY2021 earnings at ($4.59) EPS.
A number of other analysts have also recently commented on the company. Cantor Fitzgerald restated a “buy” rating and issued a $27.00 price target on shares of Spero Therapeutics in a research report on Monday, April 2nd. Zacks Investment Research upgraded Spero Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 21st. Finally, ValuEngine upgraded Spero Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. Spero Therapeutics has a consensus rating of “Hold” and a consensus price target of $24.25.
Spero Therapeutics (NASDAQ:SPRO) last issued its quarterly earnings results on Monday, April 2nd. The company reported ($1.59) EPS for the quarter, topping analysts’ consensus estimates of ($1.77) by $0.18. The company had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $0.40 million.
Several large investors have recently added to or reduced their stakes in the stock. TIAA CREF Investment Management LLC purchased a new stake in shares of Spero Therapeutics during the fourth quarter worth about $103,000. California State Teachers Retirement System purchased a new stake in shares of Spero Therapeutics during the fourth quarter worth about $112,000. Dean Capital Investments Management LLC purchased a new stake in shares of Spero Therapeutics during the fourth quarter worth about $118,000. Deutsche Bank AG purchased a new stake in shares of Spero Therapeutics during the fourth quarter worth about $155,000. Finally, California Public Employees Retirement System purchased a new stake in shares of Spero Therapeutics during the fourth quarter worth about $294,000. Hedge funds and other institutional investors own 46.28% of the company’s stock.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.